Hyper Corporation Inc

XKRX:065650 (Korea (the Republic of))  
â‚© 1434.00 (-0.35%) May 24
At Loss
P/B:
1.66
Market Cap:
â‚© 74.20B ($ 54.29M)
Enterprise V:
â‚© 40.73B ($ 29.80M)
Volume:
306.48K
Avg Vol (2M):
613.62K
Volume:
306.48K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Hyper Corporation Inc ( XKRX:065650 ) from 2003 to May 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hyperoration stock (XKRX:065650) PE ratio as of May 26 2024 is 0. More Details

Hyper Corporation Inc (XKRX:065650) PE Ratio (TTM) Chart

To

Hyper Corporation Inc (XKRX:065650) PE Ratio (TTM) Historical Data

Total 1260
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Hyperoration PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-26 At Loss 2024-03-19 At Loss
2024-05-24 At Loss 2024-03-18 At Loss
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-08 At Loss
2024-04-16 At Loss 2024-02-07 At Loss
2024-04-15 At Loss 2024-02-06 At Loss
2024-04-12 At Loss 2024-02-05 At Loss
2024-04-11 At Loss 2024-02-02 At Loss
2024-04-09 At Loss 2024-02-01 At Loss
2024-04-08 At Loss 2024-01-31 At Loss
2024-04-05 At Loss 2024-01-30 At Loss
2024-04-04 At Loss 2024-01-29 At Loss
2024-04-03 At Loss 2024-01-26 At Loss
2024-04-02 At Loss 2024-01-25 At Loss
2024-04-01 At Loss 2024-01-24 At Loss
2024-03-29 At Loss 2024-01-23 At Loss
2024-03-28 At Loss 2024-01-22 At Loss
2024-03-27 At Loss 2024-01-19 At Loss
2024-03-26 At Loss 2024-01-18 At Loss
2024-03-25 At Loss 2024-01-17 At Loss
2024-03-22 At Loss 2024-01-16 At Loss
2024-03-21 At Loss 2024-01-15 At Loss
2024-03-20 At Loss 2024-01-12 At Loss

Hyper Corporation Inc (XKRX:065650) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Hyper Corporation Inc formerly Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.